Mar 29, 2026Cardiometabolic Drugs

Tirzepatide Safety in Heart-Risk Diabetes: What We Know

Tirzepatide can improve weight and glucose control, but what do cardiovascular-risk trials show about nausea, serious harm, and mortality?

tirzepatideglp-1 agonisttype 2 diabetescardiovascular risk

Read article →

Mar 21, 2026Glp 1 Agonists

47 GLP-1 Trials: What the Pooled Weight-Loss Result Means

A 47-trial GLP-1 meta-analysis found lower weight, BMI, and waist size—but pooled results hide major differences by drug and diabetes status.

tirzepatidesemaglutideglp-1 agonistliraglutide

Read article →

Mar 21, 2026Pharmacology

Semaglutide Works Broadly. Can GLP1R Genes Predict Response?

Semaglutide improves weight, glucose, and cardiovascular outcomes. A small 2025 study links GLP1R genetics to response, but testing is premature.

semaglutideglp-1 agonistweight losscardiovascular health

Read article →

Mar 18, 2026Nutrition

Semaglutide in Type 1 Diabetes: Why AID Changes the Math

Semaglutide improved weight and CGM outcomes in adults with type 1 diabetes, obesity, and automated insulin delivery, but remains off-label and unproven.

semaglutidetype 1 diabetesglp-1 agonistweight loss

Read article →

Mar 14, 2026Nutrition

GLP-1 Heart Benefits Are Real. The RAS Mechanism Isn’t.

GLP-1 drugs reduce cardiovascular events in high-risk diabetes, but the proposed renin-angiotensin mechanism remains unproven.

semaglutideglp-1 agonistcardiovascular diseasetype 2 diabetes

Read article →

Mar 13, 2026Nutrition

Liraglutide vs. Exercise for Weight Maintenance

A 52-week trial compared liraglutide, exercise, and both after weight loss. Did either change appetite, eating behavior, or sedentary time?

liraglutideglp-1 agonistappetite suppressionweight maintenance

Read article →

Feb 28, 2026Glp1 Agonists

SELECT’s Undercovered Result: Fewer Hospitalizations on Semaglutide

SELECT made headlines for fewer heart attacks and strokes. The quieter result: semaglutide also cut hospital admissions and hospital days in high-risk obesity.

semaglutideglp-1 agonistweight losscardiovascular protection

Read article →

Feb 28, 2026Metabolic Health

Semaglutide Protects Kidneys and Reverses Prediabetes in SELECT Trial

SELECT secondary analyses: semaglutide cut kidney risk 22%, diabetes progression 78% in non-diabetic obese adults. Real signal, real caveats — full breakdown.

semaglutideglp-1 agonistdiabetes preventionkidney function

Read article →